It seems that this could be the case. Even in an article that discusses ways in which M.I.T. is trying to make the patent system less inefficient there is no mention of any alternative to patent support for financing drug research.
It's good to see that M.I.T. is devoting its resources to reducing the inefficiency of the patent system, but its efforts would probably be better directed towards developing alternative mechanisms, that assumes that M.I.T. is not also prohibited from discussing alternatives.
If you enjoyed this article, please consider making a tax-deductible donation today. For over 30 years, The American Prospect has delivered independent reporting that exposes corporate power, investigates political corruption, and analyzes threats to our democracy. Unlike many media outlets, we’re not owned by billionaires or corporations—we’re powered by readers like you.
Today’s independent journalism faces unprecedented challenges. Your support makes our reporting possible and keeps our work free and accessible to all. Whether it’s $5 or $50, every contribution helps sustain our nonprofit newsroom.
Join our community of supporters and make a donation today to help keep independent journalism thriving.
Copyright 2024 | The American Prospect, Inc. | All Rights Reserved
